{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:53:19Z","timestamp":1785541999506,"version":"3.56.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01122","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:26:06Z","timestamp":1538353566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Luigi","family":"Cardia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Calapai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Quattrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Arcoraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Calapai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epifanio","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5055\/jom.2015.0291","article-title":"Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate.","volume":"11","author":"Argoff","year":"2015","journal-title":"J. Opioid Manag."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011108.pub2","article-title":"Hydromorphone for cancer pain.","volume":"11","author":"Bao","year":"2016","journal-title":"Cochrane Database. Syst. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.5055\/jom.2015.0305","article-title":"Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets.","volume":"11","author":"Bartoli","year":"2015","journal-title":"J. Opioid Manag."},{"key":"B4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2165\/00003088-199529030-00005","article-title":"Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.","volume":"29","author":"Bertilsson","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"B5","first-page":"E227","article-title":"The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.","volume":"16","author":"Boswell","year":"2013","journal-title":"Pain Physician"},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.gerinurse.2016.07.004","article-title":"Long-term effectiveness and safety of once-daily, single-entity, extended-releasehydrocodonein patients of \u2265 75 years of age with moderate to severe nonmalignant and nonneuropathic pain.","volume":"38","author":"Broglio","year":"2017","journal-title":"Geriatr. Nurs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.","volume":"10","author":"Chou","year":"2009","journal-title":"J. Pain"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1016\/j.pain.2013.07.025","article-title":"Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States.","volume":"154","author":"Cicero","year":"2013","journal-title":"Pain"},{"key":"B9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0090-9556(25)06378-0","article-title":"Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog.","volume":"6","author":"Cone","year":"1978","journal-title":"Drug Metab. Dispos."},{"key":"B10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/jat\/bkv050","article-title":"Prescription opioids. IV: disposition of hydrocodone in oral fluid and blood following single-dose administration.","volume":"39","author":"Cone","year":"2015","journal-title":"J. Anal. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/jat\/bkt066","article-title":"Prescription opioids. II. Metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration.","volume":"37","author":"Cone","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.sapharm.2015.02.001","article-title":"Recent developments toward the safer use of opioids, with a focus on hydrocodone.","volume":"11","author":"Covvey","year":"2015","journal-title":"Res. Soc. Adm. Pharm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/01.jcp.0000085421.74359.60","article-title":"Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.","volume":"23","author":"De Leon","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s40261-016-0466-z","article-title":"Hydrocodone bitartrate ER (Hysingla(\u00ae) ER): a review in chronic pain.","volume":"36","author":"Dhillon","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"B15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbr.2015.01.023","article-title":"Differential effects of oxycodone, hydrocodone, and morphine on the responses of D2\/D3 dopamine receptors.","volume":"1","author":"Emery","year":"2015","journal-title":"Behav. Brain Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/ACO.0b013e32814b1626","article-title":"Medications of abuse in pain management.","volume":"20","author":"Flugsrud-Breckenridge","year":"2007","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"B17","year":"2012","journal-title":"Briefing Document - Drug Safety and Risk Management Advisory Committee (DSaRM) Meeting"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/03009748909101464","article-title":"Learning factors in pain.","volume":"82","author":"Fordyce","year":"1989","journal-title":"Scand. J. Rheumatol. Suppl."},{"key":"B19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0022-3565(25)04250-8","article-title":"Addiction liabilities of morphinian, 6-methyldihydromorphine and dihydrocodeinone.","volume":"100","author":"Fraser","year":"1950","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.vascn.2015.05.003","article-title":"Abuse liability assessment of hydrocodone under current draft regulatory guidelines.","volume":"75","author":"Gauvin","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.phrs.2014.09.006","article-title":"Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.","volume":"91","author":"Gould","year":"2015","journal-title":"Pharmacol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.phrs.2016.04.012","article-title":"Gender difference in prescription opioid abuse: a focus on oxycodone and hydrocodone.","volume":"108","author":"Graziani","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/15360288.2012.757575","article-title":"Assessment of extended-release opioid analgesics for the treatment of chronic pain.","volume":"27","author":"Gudin","year":"2013","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1080\/15563650.2017.1388087","article-title":"Annual report of the American association of poison control centers\u2019 national poison data system (n.d.): 34th annual report.","volume":"55","author":"Gummin","year":"2017","journal-title":"Clin. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.2651","article-title":"Association of hydrocodone schedule change with opioid prescriptions following surgery.","author":"Habbouche","year":"2018","journal-title":"JAMA Surg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/JPR.S83930","article-title":"Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain.","volume":"15","author":"Hale","year":"","journal-title":"J. Pain Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.5055\/jom.2015.0304","article-title":"Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.","volume":"11","author":"Hale","year":"","journal-title":"J. Opioid Manag."},{"key":"B28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.5055\/jom.2015.0292","article-title":"Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.","volume":"11","author":"Hale","year":"","journal-title":"J. Opioid Manag."},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5055\/jom.2016.0326","article-title":"Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: safety, maintenance of analgesia, and abuse potential.","volume":"12","author":"Hale","year":"","journal-title":"J. Opioid Manag."},{"key":"B30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/pmt-2015-0005","article-title":"Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.","volume":"6","author":"Hale","year":"","journal-title":"Pain Manag."},{"key":"B31","first-page":"467","article-title":"Hydrocodone use and sensorineural hearing loss.","volume":"10","author":"Ho","year":"2007","journal-title":"Pain Physician"},{"key":"B32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1365-2125.2003.02002.x","article-title":"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.","volume":"57","author":"Hutchinson","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clinthera.2015.12.003","article-title":"Pharmacokinetic profile and sustained 24-hour analgesia of a once-daily hydrocodone bitartrate extended-release tablet with abuse-deterrent properties.","volume":"38","author":"Kapil","year":"2016","journal-title":"Clin. Ther."},{"key":"B34","first-page":"e41","article-title":"Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000\u20132010.","volume":"6","author":"Kenan","year":"2012","journal-title":"Open Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1124\/jpet.301.2.698","article-title":"Relative reinforcing effects of three opioids with different durations of action.","volume":"301","author":"Ko","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/JPR.S33062","article-title":"Extended-release hydrocodone - gift or curse?","volume":"6","author":"Krashin","year":"2013","journal-title":"J. Pain Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamainternmed.2015.0914","article-title":"Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.","volume":"175","author":"Larochelle","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/hep.20948","article-title":"Acute liver failure study group. acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.","volume":"42","author":"Larson","year":"2005","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3109\/00498254.2012.715697","article-title":"Update on hydrocodone metabolites in rats and dogs aided with a semi-automatic software for metabolite identification mass-metasite.","volume":"43","author":"Li","year":"2013","journal-title":"Xenobiotica"},{"key":"B40","first-page":"154","article-title":"The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone.","volume":"45","author":"Lurcott","year":"1998","journal-title":"Anesth. Prog."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.01.372","article-title":"Long-term safety and effectiveness of once daily, single-entity, abuse-deterrent hydrocodone in chronic nonmalignant and nonneuropathic pain: results of a long-term open-label study.","volume":"15","author":"Lynch","year":"2014","journal-title":"J. Pain"},{"key":"B42","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/00000542-197505000-00021","article-title":"Relative analgesic potencies of morphine and hydromorphone in postoperative pain.","volume":"42","author":"Mahler","year":"1975","journal-title":"Anesthesiology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pbb.2004.12.002","article-title":"A preclinical comparison between different opioids: antinociceptive versus adverse effects.","volume":"80","author":"Meert","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1200\/JCO.2013.51.8662","article-title":"New opioids.","volume":"32","author":"Mercadante","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1073\/pnas.0136822100","article-title":"Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences.","volume":"100","author":"Mitrovic","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B46","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/15563650.2016.1245421","article-title":"Annual report of the American Association of Poison Control Centers\u2019 National Poison Data System (n.d.): 33rd annual report.","volume":"54","author":"Mowry","year":"2016","journal-title":"Clin. Toxicol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2844","article-title":"A Review of the opioid analgesic benzhydrocodone-acetaminophen.","volume":"10","author":"Mustafa","year":"2018","journal-title":"Cureus"},{"key":"B48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3810\/pgm.2013.01.2627","article-title":"Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic non cancer pain.","volume":"125","author":"Nicholson","year":"2013","journal-title":"Postgrad. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/clpt.1993.177","article-title":"CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.","volume":"54","author":"Otton","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1515\/cclm-2016-0990","article-title":"Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.","volume":"55","author":"Pantano","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update.","volume":"6","author":"Pathan","year":"2012","journal-title":"Br. J. Pain"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.105.094276","article-title":"Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.","volume":"316","author":"Peckham","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/pm\/pnx022","article-title":"Effectiveness and safety of once-daily extended-release hydrocodone in individuals previously receiving immediate-release oxycodone for chronic pain.","volume":"19","author":"Pergolizzi","year":"2017","journal-title":"Pain Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/pme.12377","article-title":"Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.","volume":"15","author":"Rauck","year":"2014","journal-title":"Pain Med."},{"key":"B55","first-page":"E161","article-title":"Profound hearing loss associated with oxycodone-acetaminophen abuse.","volume":"37","author":"Rigby","year":"2008","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"B56","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/pm\/pnw182","article-title":"Association between commonly prescribed opioids and androgen deficiency in men: a retrospective cohort analysis.","volume":"18","author":"Rubinstein","year":"2017","journal-title":"Pain Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.forsciint.2014.11.031","article-title":"Evaluation and comparison of postmortem hydrocodone concentrations in peripheral blood, central blood, and liver specimens: a minimal potential for. (redistribution).","volume":"247","author":"Saitman","year":"2015","journal-title":"Forensic Sci. Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/j.pain.2013.05.053","article-title":"Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.","volume":"154","author":"Smith","year":"2013","journal-title":"Pain"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00654","article-title":"Pharmacotoxicology of non-fentanyl derived new synthetic opioids.","volume":"20","author":"Solimini","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011604.pub2","article-title":"Hydromorphone for neuropathic pain in adults.","volume":"5","author":"Stannard","year":"2016","journal-title":"Cochrane Database. Syst. Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cca.2013.11.015","article-title":"Hydrocodone in postoperative personalized pain management: pro-drug or drug?","volume":"429","author":"Stauble","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"B62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/00325481.2016.1134022","article-title":"Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.","volume":"128","author":"Taber","year":"2016","journal-title":"Postgrad. Med."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.06.018","article-title":"Postoperative opioid prescribing practices and the impact of the hydrocodone schedule change.","author":"Tan","year":"2018","journal-title":"Surgery"},{"key":"B64","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/syn.21577","article-title":"Hydrocodone and morphine possess similar rewarding effects and reduce ERK and CREB phosphorylation in the nucleus accumbens.","volume":"66","author":"Tenayuca","year":"2012","journal-title":"Synapse"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/j.pain.0000000000000160","article-title":"A classification of chronic pain for ICD-11.","volume":"156","author":"Treede","year":"2015","journal-title":"Pain"},{"key":"B66","first-page":"S5","article-title":"Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians\u2019 (ASIPP) Guidelines.","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"B67","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/jat\/bks058","article-title":"Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers.","volume":"36","author":"Valtier","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2013.52.8356","article-title":"Nonopioid drugs in the treatment of cancer pain.","volume":"32","author":"Vardy","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain: misconceptions and mitigation strategies.","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs.","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/PGPM.S23422","article-title":"Pharmacogenomic considerations in opioid analgesia.","volume":"5","author":"Vuilleumier","year":"2012","journal-title":"Pharmgenomics Pers. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.drugalcdep.2008.05.007","article-title":"The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.","volume":"98","author":"Walsh","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1517\/14656566.2015.1060221","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.","volume":"16","author":"Wen","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2008.11.013","article-title":"Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.","volume":"101","author":"Zacny","year":"2009","journal-title":"Drug Alcohol Depend."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:25:35Z","timestamp":1761063935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":74,"alternative-id":["10.3389\/fphar.2018.01122"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01122","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]},"article-number":"1122"}}